Reported 8 months ago
Recent reports of the Omicron variant causing a rise in COVID-19 cases have drawn attention to the biomedical sector. Despite uncertainty about the direct impact of such news on biomedical stocks and funds, the suppressed prices and clear future prospects of biomedical stocks suggest a favorable entry point. Companies focusing on vaccine development and the healthcare sector, particularly in novel treatments for metabolic diseases like obesity and central nervous system disorders, are experiencing a surge in stock prices. The market is optimistic about advancements in the biotech industry, driven by ongoing clinical data releases and increased merger and acquisition activities by pharmaceutical companies to offset revenue declines from patent expirations.
Source: YAHOO